title: Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis.
abstract: Patients with systemic sclerosis (SSc) have an increased risk of malignancy compared with the general population. Recently, SSc patients with anti-RNA polymerase III antibody have been reported to have an increased risk of malignancy as compared with those with other disease-specific autoantibodies in US, European and Australian populations. Therefore, we studied the relationship between disease-specific autoantibodies and malignancy in 261 Japanese SSc patients. The prevalence of malignancy was significantly higher in patients with anti-RNA polymerase III antibody (7/22, 31.8%) than in those with anti-topoisomerase I antibody (2/82, 2.4%) and in those with anticentromere antibody (8/137, 5.8%). Importantly, among seven patients with anti-RNA polymerase III antibody and malignancy, three patients (42.9%) developed malignancy from 6 months before to 12 months after SSc onset. Thus, malignancy complication in Japanese SSc patients with anti-RNA polymerase III antibody is as high as that in other races, suggesting that SSc patients with anti-RNA polymerase III antibody share the same pathological process among different ethnic groups.
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Saigusa
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asano
authors.forename: Kouki
authors.initials: K
authors.lastname: Nakamura
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Miura
authors.forename: Yohei
authors.initials: Y
authors.lastname: Ichimura
authors.forename: Takehiro
authors.initials: T
authors.lastname: Takahashi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Toyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Shinji
authors.initials: S
authors.lastname: Noda
authors.forename: Naohiko
authors.initials: N
authors.lastname: Aozasa
authors.forename: Kaname
authors.initials: K
authors.lastname: Akamata
authors.forename: Hayakazu
authors.initials: H
authors.lastname: Sumida
authors.forename: Miki
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Zenshiro
authors.initials: Z
authors.lastname: Tamaki
authors.forename: Koichi
authors.initials: K
authors.lastname: Yanaba
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kuwano
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood*; D004264:DNA Topoisomerases, Type I / Q000276:immunology; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000208:ethnology*; D012320:RNA Polymerase III / Q000276:immunology*; D012595:Scleroderma, Systemic / Q000097:blood*
chemical_list: D000974:Antibodies, Antinuclear; C538950:anticentromere antibody; D012320:RNA Polymerase III; D004264:DNA Topoisomerases, Type I
keywords: Japanese; anti-RNA polymerase III antibody; malignancy; synchronous onset; systemic sclerosis